$SYK

Barclays initiated coverage on 26 medical technology companies, rating Stryker (SYK) and Abbott Laboratories (ABT) as Overweight. The firm sees current valuations as attractive and expects revenue stabilization to boost sentiment. Price targets: SYK at $375, ABT at $120.

Baird reiterated an Outperform rating and $385 price target for Stryker (SYK) after its planned CEO transition. The stock is down 20% year-to-date. Analysts have mixed reactions, with some lowering estimates due to orthopedic and Inari issues, while others remain optimistic about the transition.

Truist Securities lowered its price target for Stryker Corp. (SYK) to $310 from $340, maintaining a Hold rating. The stock is down 18% year-to-date. The adjustment follows Stryker's CEO transition announcement, with Spencer Stiles set to replace Kevin Lobo in 2027. Truist also revised revenue and earnings forecasts downward, citing management commentary. Multiple analysts have recently adjusted their price targets and estimates for Stryker.

Needham reiterated a Buy rating and $418 price target on Stryker (SYK) after the company announced CEO transition. Spencer Stiles will replace Kevin Lobo in 2027. Stryker's stock is near its 52-week low at $280.82, but InvestingPro suggests it is undervalued. The company reported $25.84B revenue over the last 12 months with 8.5% growth. Analysts have mixed revisions on revenue and growth projections.

Stryker (SYK) and Neogenomics (NEO) announced CEO transitions. Kevin Lobo will become executive chair at Stryker, with Spencer Stiles succeeding him in 2027. Tony Zook will be replaced at Neogenomics. SYK stock rose, while NEO fell.

Stryker (SYK) shares fell 2.2% in pre-market trading following a CEO succession announcement. Kevin Lobo will transition to Executive Chair, with Spencer Stiles becoming CEO in 2027. The company faces operational challenges, including supply chain disruptions and cybersecurity incident costs, leading to reduced price targets and trading near a 52-week low of $267. The broader market is up, indicating the drop is company-specific.

Stryker (NYSE:SYK) announced leadership changes, with Kevin Lobo transitioning to Executive Chair and Spencer Stiles becoming CEO on January 1, 2027. Lobo's tenure saw net sales triple to $26 billion, with 60+ acquisitions. Stiles, a 30-year Stryker veteran, will lead the company's growth strategy.

Stryker, a medical technology company, introduced Mako 4 SmartRobotics™ in India for robotic-assisted joint replacement. The system combines patient-specific planning, robotic technology, and haptic guidance. It has supported over 2.5 million procedures globally.

General Dynamics (GD) stock has gained 80.3% over 5 years, but its current valuation is questioned. A $49.3M contract for Stryker vehicles may support future cash flows. The company's free cash flow is $6.6B, and DCF models suggest it may be undervalued by 28%. The stock's next move depends on whether its price reflects intrinsic value based on cash flows.

The FDA often approves drugs with postmarket safety studies, but many are delayed. Tavneos, a drug by Amgen, is one example with delays and reported liver damage cases. KFF Health News found hundreds of delayed studies, raising concerns about patient safety and wasted resources. The FDA defends its approach, citing legitimate reasons for delays. Companies like Pfizer and Amgen are working to complete their studies. The delays can leave patients and doctors uncertain about risks and benefits.